Valuation: Exact Sciences Corporation

Market Cap 20.03B 17.53B 16.18B 15.09B 28.44B 1,893B 28.95B 194B 75.35B 934B 75.24B 73.56B 3,255B P/E 2024
-10.1x
P/E 2025 -92.2x
Enterprise Value 21.6B 18.9B 17.45B 16.28B 30.67B 2,042B 31.22B 209B 81.26B 1,008B 81.14B 79.32B 3,510B EV / Sales 2024
4.4x
EV / Sales 2025 6.42x
Free-Float
98.24%
Yield 2024 *
-
Yield 2025 -
1 day+0.95%
6 months+2.92%
Current year+3.30%
Current year 101.51
Extreme 101.51
104.98
1 year 38.81
Extreme 38.8118
104.98
3 years 38.81
Extreme 38.8118
104.98
5 years 29.27
Extreme 29.27
125.6
10 years 11.48
Extreme 11.48
159.54
Date Insider Type Main position Quantity % Market Cap.
23/03Free

Executive/Senior Manager

199,374 0.1044%
23/03Issuer sale

Director

57,962 0.0304%
23/03Free

Chief Financial Officer

261,465 0.1370%
Change 5-day change 1-year change 3-year change Capi.($)
+0.95%-.--%+95.55%+11.27% 20.03B
-2.43%+9.18%+117.28%+130.59% 4.8B
+0.23%+24.49%+84.12%+219.67% 3.42B
-2.34%-4.16%-28.70%-41.77% 2.03B
-1.19%-6.31%+141.86%-40.91% 1.88B
-2.66%+13.46%+45.85%+235.29% 1.51B
-2.35%+16.20%+158.92%-49.80% 943M
-2.46%+9.59%-10.00%+44.17% 910M
+6.50%-1.73%+24.13% - 506M
-1.37%-6.17%-38.23%-20.03% 474M
Average -0.60%+8.92%+59.08%+54.28% 3.65B
Weighted average by Cap. -0.07%+5.55%+87.04%+49.54%

Financials

2024 2025
Net sales 2.76B 2.41B 2.23B 2.08B 3.92B 261B 3.99B 26.74B 10.38B 129B 10.37B 10.13B 448B 3.25B 2.84B 2.62B 2.45B 4.61B 307B 4.69B 31.47B 12.22B 151B 12.2B 11.93B 528B
Net income -1.03B -901M -831M -775M -1.46B -97.28B -1.49B -9.97B -3.87B -48B -3.87B -3.78B -167B -208M -182M -168M -157M -295M -19.66B -301M -2.02B -782M -9.7B -781M -764M -33.8B
Net Debt 1.74B 1.52B 1.4B 1.31B 2.47B 164B 2.51B 16.84B 6.54B 81.08B 6.53B 6.38B 282B 1.57B 1.37B 1.27B 1.18B 2.23B 148B 2.27B 15.22B 5.91B 73.26B 5.9B 5.77B 255B
Logo Exact Sciences Corporation
Exact Sciences Corporation is a provider of cancer screening and diagnostic tests. The Company provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. It is focusing its research and development efforts on three main areas: Colorectal Cancer Screening Test Development, MCED Test Development and MRD Test Development. Its products and services include Cologuard test, Oncotype DX Breast Recurrence Score Test, Oncotype DX Breast DCIS Score Test, Oncotype DX Colon Recurrence Score Test, OncoExTra Test, and Riskguard Test. Its flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Oncotype DX Breast Recurrence Score test examines the activity of 21 genes in a patient’s breast tumor tissue.
Employees
7,150
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
AAA
  1. Stock Market
  2. Stocks
  3. EXAS Stock